Use of oral anticoagulants and risk of prostate cancer: a population-based case–control study in Montreal, Canada

Cancer Causes and Control

Volumn 25, Issue 9, 2014, Pages 1159-1166

  Blanc Lapierre, Audrey ^a   Weiss, Deborah ^a   Parent, Marie Élise ^a,b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Anticoagulants; Case control study; Coumarins; Prostate cancer; Risk factors

Indexed keywords

ANTICOAGULANT AGENT;

AGE; AGED; BODY MASS; CANADA; CASE CONTROL STUDY; ETHNIC GROUP; ETHNOLOGY; HUMAN; INTERVIEW; MALE; MIDDLE AGED; ODDS RATIO; ORAL DRUG ADMINISTRATION; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICAL MODEL;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; BODY MASS INDEX; CASE-CONTROL STUDIES; ETHNIC GROUPS; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; QUEBEC; RISK FACTORS;

EID: 84939880579     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0417-z     Document Type: Article

References (22)

1. International Agency for Research on Cancer (2010) Globocan 2008. http://globocan.iarc.fr/. Accessed 7 Oct 2013
2. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci J Virtual Libr 11:1388–1413
3. Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: trousseau’s syndrome revisited. Blood 62:14–31
4. Iodice S, Gandini S, Löhr M et al (2008) Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost 6:781–788. doi:10.1111/j.1538-7836.2008.02928.x
5. Baron JA, Gridley G, Weiderpass E et al (1998) Venous thromboembolism and cancer. Lancet 351:1077–1080. doi:10.1016/S0140-6736(97)10018-6
6. Windholz M, Budavari S, Blumetti RF, Otterbein ES (1983) The Merck Index, 10th edn. Merck & Co, Rahway, NJ, p 9860
7. Sørensen HT, Johnsen SP, Nørgård B et al (2003) Cancer and venous thromboembolism: a multidisciplinary approach. Clin Lab 49:615–623
8. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol Off J Am Soc Clin Oncol 27:4902–4911. doi:10.1200/JCO.2009.22.4584
9. Bobek V, Kovarík J (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58:213–219. doi:10.1016/j.biopha.2003.11.007
10. Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:1149–1161. doi:10.1002/cncr.22892
11. Akl EA, Kamath G, Kim SY et al (2007) Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 26:175–184
12. Zhang J, Zhang Y-L, Ma K-X, Qu J-M (2013) Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 68:442–450. doi:10.1136/thoraxjnl-2012-202592
13. Taliani MR, Agnelli G, Prandoni P et al (2003) Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 1:1730–1733
14. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342:1953–1958. doi:10.1056/NEJM200006293422604
15. Tagalakis V, Tamim H, Blostein M et al (2007) Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 8:395–402. doi:10.1016/S1470-2045(07)70046-3
16. Pengo V, Noventa F, Denas G et al (2011) Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 117:1707–1709. doi:10.1182/blood-2010-08-304758
17. Parent M-É, Goldberg MS, Crouse DL et al (2013) Traffic-related air pollution and prostate cancer risk: a case-control study in Montreal, Canada. Occup Environ Med 70:511–518. doi:10.1136/oemed-2012-101211
18. Agnelli G, Taliani MR, Prandoni P, WODIT Investigators (2008) More on: vitamin K antagonists and cancer. J Thromb Haemost 6:1441–1442; author reply 1442–1443. doi:10.1111/j.1538-7836.2008.03044.x
19. Tagalakis V, Tamim H (2010) The effect of warfarin use on clinical stage and histological grade of prostate cancer. Pharmacoepidemiol Drug Saf 19:436–439. doi:10.1002/pds.1943
20. Ahern TP, Pedersen L, Sværke C et al (2011) The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol 174:1382–1390. doi:10.1093/aje/kwr268
21. Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619–625
22. Noize P, Bazin F, Pariente A et al (2012) Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class. J Clin Epidemiol 65:1061–1068. doi:10.1016/j.jclinepi.2012.04.009